Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company’s leading position is already being tested by Novo Nordisk’s GLP-1 weight loss pill.
Source: https://www.fool.com/investing/2026/01/23/forget-eli-lilly-b…
In this video, I will discuss two undervalued companies that have experienced a decent pullback in 2025 and expect to show fundamental improvements in 2026.
Oracle’s (ORCL) second-quarter revenue miss, coupled with a disappointing profit outlook, is sending shockwaves through the tech sector today.
CIEN, DG and CMC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2026.
